Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion type Assertion NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_head.
- NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion wasGeneratedBy ECO_0000203 NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_provenance.
- NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion wasDerivedFrom befree-20150227 NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_provenance.
- NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion SIO_000772 18847555 NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_provenance.
- NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion evidence source_evidence_literature NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_provenance.
- NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_assertion description "[Primary screening with Hybrid Capture((R)) 2 (HC2) generally detects more than 90% of all CIN2, CIN3 or cancer cases, and is 25% (95% CI): 15-36%) relatively more sensitive than cytology at a cut-off of abnormal squamous cells of undetermined significance (ASC-US) (or low-grade squamous intraepithelial lesions (LSIL) if ASC-US unavailable), but is 6% (95% CI: 4-7%) relatively less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP444967.RABaHe9wZEhHk4dPS3iQpr9yz3jPFygYbJbMqaC8nnifU130_provenance.